The availability of ribavirin manufacturers has had a profound impact on global health, particularly in the treatment of chronic hepatitis C. Hepatitis C is a major cause of liver cirrhosis and liver cancer, and Ribavirin, when used in combination with other drugs, has significantly improved treatment outcomes for patients. The drug has helped to lower viral loads in patients, reduce symptoms, and, in many cases, clear the virus from the body.

For infants and young children, Ribavirin has been used to treat severe cases of respiratory syncytial virus (RSV) infection. RSV can cause serious respiratory issues in young children, leading to hospitalization. Ribavirin, administered as an aerosol, helps reduce the severity of the infection and improve recovery times, potentially saving lives.